Anti Cd 20 Ocrevus denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Ocrevus as Experimental

A BCBS experimental or investigational denial for Ocrevus (ocrelizumab) most commonly occurs in one of three situations: the submitted indication does not align with the FDA-approved label (an off-label use), there is a mismatch between the diagnosis code submitted and BCBS's benefit criteria, or the specific BCBS plan entity has not updated its medical policy to reflect the drug's current approval status. BCBS is a federation of regional plans, and medical policy updates are not always synchronized across entities — so the applicable policy depends on which BCBS plan administers your benefit.

For any on-label use of Ocrevus, this denial is factually incorrect and is among the most appealable denial types. The FDA approval record is a public, verifiable document.

## Federal Appeal Rights

• Internal appeal: File under ERISA §503 (employer plan) or applicable ACA or state rules. Experimental-or-investigational denials are subject to mandatory internal review. Deadlines are on your denial letter.
• External review: ACA §2719 explicitly requires that experimental/investigational denials be subject to external review by an IRO. This is one of the strongest external-review categories for enrollees, because the IRO applies objective medical evidence standards and the FDA record — not BCBS's internal policy — as the benchmark.
• Peer-to-peer review: Before filing a formal appeal, the prescribing neurologist should request an urgent peer-to-peer call with the BCBS medical director who issued the denial. Many experimental denials for on-label uses are resolved at this stage.
• Expedited review: Available when delay poses serious health risk.

## What to Gather

1. FDA label for ocrelizumab — download from DailyMed (dailymed.nlm.nih.gov). Print the "Indications and Usage" section. This is your primary exhibit. Verify the patient's MS subtype (relapsing or primary progressive) matches an approved indication. 2. Diagnosis confirmation — neurologist notes and MRI reports confirming the MS subtype consistent with the FDA-approved indication. 3. Professional society guideline endorsement — a statement from your neurologist citing the applicable professional society guideline (American Academy of Neurology, National MS Society) supporting ocrelizumab for this patient's diagnosis. Do not cite specific trial names or statistics; cite the organization and guideline title only. 4. BCBS medical policy — identify the specific BCBS plan entity (state/regional) and download its current medical policy for ocrelizumab. If the policy is outdated relative to the FDA approval, note the discrepancy explicitly in your appeal letter. 5. Prescriber rebuttal letter — factual, concise, citing the FDA label and connecting the approved indication to this patient's confirmed diagnosis.

## Criteria-Mapping Structure

| Denial Basis | Rebuttal Documentation | |---|---| | Drug asserted experimental | FDA label "Indications and Usage" from DailyMed | | Off-label use alleged | Diagnosis code match to FDA indication; neuro note | | BCBS policy outdated | FDA approval date vs. BCBS policy effective date | | Not endorsed by professional societies | Neurologist letter citing applicable guideline organization |

Leading with the FDA label is the fastest path to reversal. Attach it as Exhibit A and reference it in the opening paragraph of your appeal letter. For external review, the IRO will apply the FDA record directly — making documentation of the on-label indication your most powerful asset.